Table_5.docx | | 2019 |
Table_4.docx | | 2019 |
Table_3.docx | | 2019 |
Table_2.docx | | 2019 |
Table_1.docx | | 2019 |
Data_Sheet_1.PDF | | 2018 |
Chapter 9 Nanomaterials and Nanotechnologies for Photon Radiation Enhanced Cancer Treatment | NATO Science for Peace and Security Series B: Physics and Biophysics | 2018 |
Arzneiverordnungen 2014 im Überblick | | 2015 |
Readability Analysis of the Package Leaflets for Biological Medicines Available on the Internet Between 2007 and 2013: An Analytical Longitudinal Study | Journal of Medical Internet Research | 2016 |
Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database | Drugs - Real World Outcomes | 2021 |
Changes in Multimorbidity and Polypharmacy Patterns in Young and Adult Population over a 4-Year Period: A 2011-2015 Comparison Using Real-World Data | International Journal of Environmental Research and Public Health | 2021 |
Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval | British Journal of Clinical Pharmacology | 2020 |
A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA | Therapeutic Innovation and Regulatory Science | 2019 |
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology | Drug Safety | 2019 |
Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology | Drug Safety | 2019 |
Patterns of multimorbidity and polypharmacy in young and adult population: Systematic associations among chronic diseases and drugs using factor analysis | PLoS ONE | 2019 |
Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report : Radiation/systemic drug combo in metastatic melanoma | Cancer Chemotherapy and Pharmacology | 2019 |
Global Disparities: Can the World Afford Cancer? | | 2019 |
Summary of Torsades de Pointes (TdP) Reports Associated with Intravenous Drug Formulations Containing the Preservative Chlorobutanol | Drug Safety | 2019 |
HIV care cost in England: a cross-sectional analysis of antiretroviral treatment and the impact of generic introduction | HIV Medicine | 2019 |
Complexity of Biologics CMC Regulation | | 2019 |
Research and development of mAb drugs in China: a look from policy perspectives | Human Vaccines and Immunotherapeutics | 2019 |
Readability assessment of package leaflets of biosimilars | BMJ Open | 2019 |
Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery | PLoS ONE | 2019 |
Copies of nonbiological complex drugs: generic, hybrid or biosimilar? | Drug Discovery Today | 2019 |
Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS) | BioDrugs | 2018 |
Anti-Tumor Necrosis Factor α Therapeutics Differentially Affect Infection of Human Macrophages | Frontiers in Immunology | 2018 |
Parenteral protein formulations: An overview of approved products within the European Union | European Journal of Pharmaceutics and Biopharmaceutics | 2018 |
Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust | Oncologist | 2018 |
Appendix 3—Marketed Biotherapeutics | | 2018 |
Selected Biotherapeutics Overview | | 2018 |
Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications | Frontiers in Pharmacology | 2018 |
[Predictive value of PD-L1 diagnostics] | Der Pathologe | 2018 |
"Market withdrawals" of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations | Health Economics Review | 2018 |
Drug Interactions With New Synthetic Opioids | Frontiers in Pharmacology | 2018 |
EU Perspective on Biosimilars | AAPS Advances in the Pharmaceutical Sciences Series | 2018 |
Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease | Gastroenterología Y Hepatología | 2018 |
Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants | Oncotarget | 2018 |
Anti-tumour necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease | Gastroenterología Y Hepatología (English Edition) | 2018 |
Recommendations for the design of small population clinical trials | Orphanet Journal of Rare Diseases | 2018 |
Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany | Value in Health | 2018 |
Sample Size for Multiple Hypothesis Testing in Biosimilar Development | Statistics in Biopharmaceutical Research | 2018 |
Portrait of women with type 1 or type 2 diabetes of childbearing age attending diabetes clinics in Italy: the AMD-Annals initiative | Acta Diabetologica | 2018 |
Quantitative Estimation of Plasma Free Drug Fraction in Patients With Varying Degrees of Hepatic Impairment: A Methodological Evaluation | Journal of Pharmaceutical Sciences | 2018 |
Conflicting meal recommendations for oral oncology drugs: pose risks to patient care? | European Journal of Clinical Pharmacology | 2018 |
Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms | Pharmacology & Therapeutics | 2018 |
Anticoagulant prophylaxis and therapy in children: current challenges and emerging issues | Journal of Thrombosis and Haemostasis | 2018 |
Immunogenicity Assessment of Biosimilars | Pharmaceutical Medicine | 2018 |
An F-Labeled Poly(ADP-ribose) Polymerase Positron Emission Tomography Imaging Agent | Journal of Medicinal Chemistry | 2018 |
Extension Study of PF-05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis | Arthritis Care and Research | 2018 |